New vaccine trial aims to train body to destroy breast cancer cells
NCT ID NCT05455658
Summary
This study is testing an experimental vaccine called STEMVAC in people with early-stage triple-negative breast cancer who have already finished their standard treatments. The goal is to see if the vaccine can safely 'wake up' the immune system to recognize and attack specific proteins found on breast cancer cells, potentially helping to prevent the cancer from coming back. Researchers will measure the immune system's response to the vaccine and track participants' health for five years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21287, United States
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.